1. Home
  2. QUAD vs NGEN Comparison

QUAD vs NGEN Comparison

Compare QUAD & NGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Quad Graphics Inc

QUAD

Quad Graphics Inc

HOLD

Current Price

$6.52

Market Cap

340.8M

ML Signal

HOLD

NGEN

NervGen Pharma Corp. Common stock

N/A

Current Price

$3.66

Market Cap

317.6M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
QUAD
NGEN
Founded
1971
2017
Country
United States
Canada
Employees
10100
N/A
Industry
Publishing
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
340.8M
317.6M
IPO Year
2010
N/A

Fundamental Metrics

Financial Performance
Metric
QUAD
NGEN
Price
$6.52
$3.66
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
$9.90
N/A
AVG Volume (30 Days)
214.1K
94.6K
Earning Date
04-28-2026
04-02-2026
Dividend Yield
6.07%
N/A
EPS Growth
150.47
N/A
EPS
0.54
N/A
Revenue
$2,419,900,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$12.20
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.50
$3.55
52 Week High
$7.54
$5.93

Technical Indicators

Market Signals
Indicator
QUAD
NGEN
Relative Strength Index (RSI) 45.92 36.39
Support Level $6.38 N/A
Resistance Level $6.82 $4.44
Average True Range (ATR) 0.20 0.23
MACD -0.02 -0.00
Stochastic Oscillator 30.77 20.55

Price Performance

Historical Comparison
QUAD
NGEN

About QUAD Quad Graphics Inc

Quad/Graphics Inc provides print and marketing services to help customers market their products, services, and contents. The company operates in the commercial segment of the printing industry. It operates through three divisions. The United States print and related services segment consists of the company's American operations. Besides the complete set of print and marketing solutions, this segment also manufactures ink. The international segment includes the company's printing business in Europe and Latin America and others countries. The corporate segment is engaged in the general and administrative activities as well as associated costs. The company almost generates all its revenue from the American domestic market..

About NGEN NervGen Pharma Corp. Common stock

NervGen Pharma Corp is a clinical-stage biotech company. The company's principal business activity is the discovery, development, and commercialization of pharmaceutical treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. The company's initial target indication is spinal cord injury. The company's pipeline products include NVG-291 and NVG-300.

Share on Social Networks: